Xiaoxiang Chen

Academic / Other · 5 registered clinical trials.

Status	Trial	Phase	Started
Unknown	Variance of HRD From Paired Ovarian Cancer Ovarian Cancer, HRD, Platinum-sensitive Ovarian Cancer	—	2021-10-01
Unknown	Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients Ovarian Cancer, HRD, PARP Inhibitor	—	2021-09-15
Unknown	The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer Ovarian Cancer, Clinical Marker, PARP Inhibitor	—	2020-12-15
Unknown	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Ovarian Neoplasms, Fallopian Tube Neoplasms, Endocrine Gland Neoplasms	Phase 2	2020-11-06
Unknown	Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Ovarian Cancer, Ovarian and Fallopian Tube Cysts and Neoplasms, Neoplasms by Site	Phase 2	2020-10-28